MarketPulse — Real-Time Financial News & Market Analysis

Collate launches AI Studio with semantic intelligence platform enabling enterprises to deploy AI agents that accurately understand complex organizational data, addressing reliability concerns in enterprise AI.

Vistagen Therapeutics shareholders must file for lead plaintiff status by March 16, 2026 in securities fraud lawsuit alleging false statements and undisclosed risks.

Rogers launches GO Anywhere Plus, a satellite-IoT service for remote asset tracking across Canada, partnering with Geotab to extend fleet management beyond cellular coverage areas.

Rogers launches GO Anywhere Plus, a satellite IoT service for asset tracking in remote Canadian regions where cellular networks don't reach, partnering with Geotab.

Intel gains 1.40% in premarket trading after partnering with SambaNova Systems to integrate Xeon processors into AI systems, replacing AMD chips.

Buffett's core holdings—Apple, Coca-Cola, Chevron, Visa, Domino's—exemplify enduring wealth-creation through competitive advantages, consistent cash flows, and shareholder returns across economic cycles.

TopBuild acquires Johnson Roofing for $29M revenue, expanding commercial roofing services across Texas, Louisiana, and Oklahoma.

Treasury yields fell 25 basis points in a week on softer-than-expected inflation data, prompting investors to reassess rate expectations and reposition portfolios.

BWX Technologies beat Q4 expectations with strong nuclear and defense demand. The company's $7.3B backlog and optimistic 2026 guidance reflect robust market confidence.

CoreWeave's stock surged 140% with strong 133% sales growth, but the company faces profitability concerns, $19B debt, and dangerous customer concentration with two clients representing 77% of revenue.

Prediction markets give Nvidia 95% odds of beating earnings expectations Wednesday, buoyed by four consecutive quarters of surpassing estimates and strong AI/data center demand.

Global anti-snoring devices market projected to nearly double to $3.36 billion by 2033, driven by obesity, health awareness, and technological advances.

Aclaris launches Phase 1b asthma trial for ATI-052, a dual-target antibody also in dermatitis trials. Results expected mid-2026.

Aquestive Therapeutics will report Q4 2025 results March 4 and hold investor call March 5, discussing financial performance and pipeline progress including Anaphylm™ development.

Dryden Gold Corp. upgraded to OTCQX listing effective February 24, 2026, enhancing trading access and visibility for U.S. investors through improved liquidity and transparency standards.

Beam Therapeutics secures $500M credit facility from Sixth Street Partners to fund commercial launch of its sickle cell therapy, with payments tied to clinical and regulatory milestones.

Fulcrum's pociredir shows strong fetal hemoglobin gains in sickle cell Phase 1b trial, with 58% of patients reaching therapeutic levels and reduced pain crises.

Autolus to present pipeline updates and 2025 financial results at two March 2026 healthcare conferences, discussing commercial progress and strategic priorities.

Atea's AT-587 shows promise as first potential HEV treatment, demonstrating 30-150x greater antiviral activity than existing agents in preclinical studies. Phase 1 trials expected mid-2026.

Abaxx Exchange completes first physical gold delivery on Singapore futures contract, validating its operational readiness and positioning it as a key regional trading platform for precious metals.